Expert Insights

Corey Langer, MD, Abramson Cancer Center, Hospital of the University of Pennsylvania

Sponsored

Videos

Integrating QoL Analysis With Efficacy Outcomes in the Pembrolizumab KN-590 Study in First-Line Esophageal Cancer

08/05/2022

In this video, Prof Eric Van Cutsem, MD, PhD, and Marc Diez Garcia, MD, discuss new data from the Q-TWIST analysis of the phase 3 KEYNOTE-590 study of first line pembrolizumab plus chemotherapy in esopahgeal and gastroesophageal junction...

In this video, Prof Eric Van...

08/05/2022

Oncology

Podcasts

BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma

07/29/2022

Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.

Margherita Rimini, MD, discusses...

07/29/2022

Oncology

Yi-Bin Chen, MD, Massachusetts General Hospital

Videos

Itacitinib vs Placebo Combined With Corticosteroids for GVHD: Findings From the GRAVITAS-301 Trial

07/25/2022

Yi-Bin Chen, MD, discusses results from the phase 3 GRAVITAS-301 trial, which evaluated itacitinib vs placebo, both in combination with corticosteroids, for the initial treatment of patients with acute GVHD.

Yi-Bin Chen, MD, discusses...

07/25/2022

Oncology

Ruth He, MD, Lombardi Comprehensive Cancer Center

Podcasts

Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

07/22/2022

Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...

Ruth He, MD, discusses findings...

07/22/2022

Oncology

Videos

Enzalutamide Added to Testosterone Suppression Improves OS in Metastatic Hormone-Sensitive Prostate Cancer

07/21/2022

Ian Davis, MBBS, PhD, FRACP, FAChPM, discusses updated OS outcomes from the ENZAMET trial, exploring testosterone suppression plus either enzalutamide or a conventional non-steroidal anti-androgen in metastatic hormone-sensitive prostate...

Ian Davis, MBBS, PhD, FRACP,...

07/21/2022

Oncology

Arndt Vogel, MD, Hannover Medical School

Podcasts

Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

07/14/2022

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Arndt Vogel, MD, shares results...

07/14/2022

Oncology

Videos

Treating Locally Advanced Basal Cell Carcinoma

07/14/2022

Evan Lipson, MD, and Megan Schollenberger, CRNP, discuss a patient case of recurrent, locally advanced basal cell carcinoma of the left nasal ala and medial canthus, following the patient through multiple lines of therapy.

Evan Lipson, MD, and Megan...

07/14/2022

Oncology

Erika Martinelli, MD, PhD, University of Campania “Luigi Vanvitelli”

Videos

Third-Line Cetuximab Rechallenge Demonstrates Therapeutic Effectiveness in Metastatic Colorectal Cancer

07/03/2022

Erika Martinelli, MD, PhD, discusses findings from a follow-up analysis of the CRICKET and CAVE trials evaluating third-line cetuximab rechallenge combined with irinotecan or avelumab for patients with RAS wild-type metastatic colorectal...

Erika Martinelli, MD, PhD,...

07/03/2022

Oncology

Ignacio Garrido-Laguna, MD, Huntsman Cancer Institute

Videos

Entrectinib Yields Durable Responses, Manageable Safety in NTRK Fusion-Positive Gastrointestinal Cancers

07/03/2022

Ignacio Garrido-Laguna, MD, discusses findings from an updated integrated analysis exploring entrectinib in patients with NTRK fusion-positive gastrointestinal cancer.

Ignacio Garrido-Laguna, MD,...

07/03/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology